Bank of New York Mellon Corp Acquires 5,364,929 Shares of Pfizer Inc. $PFE

Bank of New York Mellon Corp grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,879,900 shares of the biopharmaceutical company’s stock after buying an additional 5,364,929 shares during the quarter. Bank of New York Mellon Corp’s holdings in Pfizer were worth $1,512,948,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Providence Wealth Advisors LLC increased its holdings in shares of Pfizer by 7.3% in the first quarter. Providence Wealth Advisors LLC now owns 43,734 shares of the biopharmaceutical company’s stock valued at $1,245,000 after purchasing an additional 2,977 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Pfizer during the first quarter worth $674,000. MASTERINVEST Kapitalanlage GmbH lifted its holdings in shares of Pfizer by 23.9% during the first quarter. MASTERINVEST Kapitalanlage GmbH now owns 57,402 shares of the biopharmaceutical company’s stock worth $1,612,000 after buying an additional 11,077 shares in the last quarter. Luts & Greenleigh Group Inc. bought a new stake in shares of Pfizer in the first quarter valued at about $207,000. Finally, Sanctuary Advisors LLC grew its position in Pfizer by 6.3% during the first quarter. Sanctuary Advisors LLC now owns 1,013,675 shares of the biopharmaceutical company’s stock worth $28,464,000 after buying an additional 59,828 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced FDA approval for PADCEV plus Keytruda in muscle-invasive bladder cancer, expanding the platinum-free regimen to a broader patient group and strengthening Pfizer’s oncology franchise. Pfizer Announces FDA Approval of PADCEV plus Keytruda in MIBC
• Positive Sentiment: Several recent articles point to upside potential for PFE, citing Wall Street price targets above the current trading range and highlighting potential benefits from Seagen integration and oncology growth. Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
• Positive Sentiment: Pfizer remains attractive to income investors thanks to its high dividend yield, which continues to support the stock’s value case even as investors wait for stronger earnings growth. Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?
• Neutral Sentiment: Analysts are watching Pfizer’s upcoming Q2 results closely, with expectations for a profit decline but possible offsets from cancer drugs, biosimilars, and pipeline updates. Here’s How Pfizer’s Oncology Growth Story Looks Ahead of Q2 Results
• Negative Sentiment: Some coverage still emphasizes pressure on earnings and the market’s cautious stance toward Pfizer ahead of results, suggesting investors remain concerned about near-term profit trends. Here’s What to Expect From Pfizer’s Next Earnings Report

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PFE shares. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. HSBC cut Pfizer from a “buy” rating to a “hold” rating and decreased their price target for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $28.50.

Pfizer Stock Up 2.1%

NYSE:PFE opened at $24.77 on Thursday. The firm’s 50 day simple moving average is $25.25 and its 200 day simple moving average is $26.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a market cap of $141.18 billion, a PE ratio of 18.91 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is presently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.